# Stereotaxis, Inc.: financial statements, quarterly

STXS · NYSE · CIK 1289340 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/stxs.md) · [Financials](/companies/stxs/financials.md) · [Filings](/companies/stxs/filings.md) · [Insiders](/companies/stxs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/stxs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [7,799](/filings/0001493152-24-045994.md) | [4,565 d](/filings/0001493152-25-010352.md) | [6,880](/filings/0001641172-25-009933.md) | [4,502](/filings/0001641172-25-023417.md) | [9,196](/filings/0001493152-25-021881.md) | [6,340 d](/filings/0001493152-26-009881.md) | [7,472](/filings/0001493152-26-022697.md) | [8,798](/filings/0001493152-26-037357.md) | [7,464](/filings/0001493152-25-021881.md) | [8,642 d](/filings/0001493152-26-009881.md) | [6,291](/filings/0001493152-26-022697.md) | [7,670](/filings/0001493152-26-037357.md) |
| Cost of revenue | $k | [3,740](/filings/0001493152-24-045994.md) | [1,827 d](/filings/0001493152-25-010352.md) | [2,914](/filings/0001641172-25-009933.md) | [1,189](/filings/0001641172-25-023417.md) | [5,097](/filings/0001493152-25-021881.md) | [3,124 d](/filings/0001493152-26-009881.md) | [3,408](/filings/0001493152-26-022697.md) | [4,219](/filings/0001493152-26-037357.md) | [3,363](/filings/0001493152-25-021881.md) | [4,315 d](/filings/0001493152-26-009881.md) | [2,497](/filings/0001493152-26-022697.md) | [3,184](/filings/0001493152-26-037357.md) |
| Gross profit | $k | [4,059](/filings/0001493152-24-045994.md) | [2,738 d](/filings/0001493152-25-010352.md) | [3,966](/filings/0001641172-25-009933.md) | [3,313](/filings/0001641172-25-023417.md) | [4,099](/filings/0001493152-25-021881.md) | [3,216 d](/filings/0001493152-26-009881.md) | [4,064](/filings/0001493152-26-022697.md) | [4,579](/filings/0001493152-26-037357.md) | [4,101](/filings/0001493152-25-021881.md) | [4,327 d](/filings/0001493152-26-009881.md) | [3,794](/filings/0001493152-26-022697.md) | [4,486](/filings/0001493152-26-037357.md) |
| Research and development | $k | [2,668](/filings/0001493152-24-045994.md) | [2,212 d](/filings/0001493152-25-010352.md) | [2,243](/filings/0001641172-25-009933.md) | [2,273](/filings/0001641172-25-023417.md) | [2,454](/filings/0001493152-25-021881.md) | [2,790 d](/filings/0001493152-26-009881.md) | [2,350](/filings/0001493152-26-022697.md) | [1,777](/filings/0001493152-26-037357.md) | [2,546](/filings/0001493152-25-021881.md) | [2,710 d](/filings/0001493152-26-009881.md) | [2,397](/filings/0001493152-26-022697.md) | [2,390](/filings/0001493152-26-037357.md) |
| Operating income | $k | [(5,639)](/filings/0001493152-24-045994.md) | [(5,304) d](/filings/0001493152-25-010352.md) | [(4,746)](/filings/0001641172-25-009933.md) | [(6,021)](/filings/0001641172-25-023417.md) | [(6,345)](/filings/0001493152-25-021881.md) | [(7,627) d](/filings/0001493152-26-009881.md) | [(5,929)](/filings/0001493152-26-022697.md) | [(3,977)](/filings/0001493152-26-037357.md) | [(6,557)](/filings/0001493152-25-021881.md) | [(5,649) d](/filings/0001493152-26-009881.md) | [(5,981)](/filings/0001493152-26-022697.md) | [(4,568)](/filings/0001493152-26-037357.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(5,369)](/filings/0001493152-24-045994.md) | [(5,040) d](/filings/0001493152-25-010352.md) | [(4,507)](/filings/0001641172-25-009933.md) | [(5,833)](/filings/0001641172-25-023417.md) | [(6,190)](/filings/0001493152-25-021881.md) | [(7,515) d](/filings/0001493152-26-009881.md) | [(5,823)](/filings/0001493152-26-022697.md) | [(3,826)](/filings/0001493152-26-037357.md) | [(6,463)](/filings/0001493152-25-021881.md) | [(5,531) d](/filings/0001493152-26-009881.md) | [(5,861)](/filings/0001493152-26-022697.md) | [(4,468)](/filings/0001493152-26-037357.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001493152-24-045994.md) | not reported | [(0.06)](/filings/0001641172-25-009933.md) | [(0.07)](/filings/0001641172-25-023417.md) | [(0.08)](/filings/0001493152-25-021881.md) | not reported | [(0.07)](/filings/0001493152-26-022697.md) | [(0.05)](/filings/0001493152-26-037357.md) | [(0.07)](/filings/0001493152-25-021881.md) | not reported | [(0.06)](/filings/0001493152-26-022697.md) | [(0.05)](/filings/0001493152-26-037357.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0001493152-24-045994.md) | not reported | [(0.06)](/filings/0001641172-25-009933.md) | [(0.07)](/filings/0001641172-25-023417.md) | [(0.08)](/filings/0001493152-25-021881.md) | not reported | [(0.07)](/filings/0001493152-26-022697.md) | [(0.05)](/filings/0001493152-26-037357.md) | [(0.07)](/filings/0001493152-25-021881.md) | not reported | [(0.06)](/filings/0001493152-26-022697.md) | [(0.05)](/filings/0001493152-26-037357.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [22.1](/filings/0001493152-24-045994.md) | [19.8](/filings/0001493152-25-010352.md) | [17.6](/filings/0001641172-25-009933.md) | [14.7](/filings/0001641172-25-023417.md) | [10.7](/filings/0001493152-25-021881.md) | [12.2](/filings/0001493152-26-009881.md) | [10.6](/filings/0001493152-26-022697.md) | [7.0](/filings/0001641172-25-023417.md) | [10.5](/filings/0001493152-25-021881.md) | [13.4](/filings/0001493152-26-037357.md) | [14.6](/filings/0001493152-26-022697.md) | [10.5](/filings/0001493152-26-037357.md) |
| Current assets | $m | [35.5](/filings/0001493152-23-040354.md) | [33.3](/filings/0001493152-25-010352.md) | [31.2](/filings/0001493152-24-019608.md) | [28.1](/filings/0001493152-24-032047.md) | [28.8](/filings/0001493152-24-045994.md) | [26.4](/filings/0001493152-26-009881.md) | [25.9](/filings/0001641172-25-009933.md) | [21.9](/filings/0001641172-25-023417.md) | [26.7](/filings/0001493152-25-021881.md) | [33.8](/filings/0001493152-26-037357.md) | [36.0](/filings/0001493152-26-022697.md) | [38.0](/filings/0001493152-26-037357.md) |
| Total assets | $m | [44.5](/filings/0001493152-23-040354.md) | [41.9](/filings/0001493152-25-010352.md) | [39.5](/filings/0001493152-24-019608.md) | [36.0](/filings/0001493152-24-032047.md) | [50.9](/filings/0001493152-24-045994.md) | [46.7](/filings/0001493152-26-009881.md) | [45.7](/filings/0001641172-25-009933.md) | [41.2](/filings/0001641172-25-023417.md) | [45.6](/filings/0001493152-25-021881.md) | [52.3](/filings/0001493152-26-037357.md) | [54.0](/filings/0001493152-26-022697.md) | [55.6](/filings/0001493152-26-037357.md) |
| Current liabilities | $m | [13.0](/filings/0001493152-23-040354.md) | [13.2](/filings/0001493152-25-010352.md) | [12.9](/filings/0001493152-24-019608.md) | [12.3](/filings/0001493152-24-032047.md) | [20.7](/filings/0001493152-24-045994.md) | [21.6](/filings/0001493152-26-009881.md) | [24.2](/filings/0001641172-25-009933.md) | [20.7](/filings/0001641172-25-023417.md) | [20.4](/filings/0001493152-25-021881.md) | [22.4](/filings/0001493152-26-037357.md) | [23.1](/filings/0001493152-26-022697.md) | [26.8](/filings/0001493152-26-037357.md) |
| Total liabilities | $m | [20.2](/filings/0001493152-23-040354.md) | [20.0](/filings/0001493152-25-010352.md) | [19.4](/filings/0001493152-24-019608.md) | [19.3](/filings/0001493152-24-032047.md) | [34.7](/filings/0001493152-24-045994.md) | [35.3](/filings/0001493152-26-009881.md) | [37.5](/filings/0001641172-25-009933.md) | [34.4](/filings/0001641172-25-023417.md) | [34.1](/filings/0001493152-25-021881.md) | [33.5](/filings/0001493152-26-037357.md) | [34.4](/filings/0001493152-26-022697.md) | [38.1](/filings/0001493152-26-037357.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [18.7](/filings/0001493152-24-045994.md) | [16.3](/filings/0001493152-26-009881.md) | [14.6](/filings/0001641172-25-023417.md) | [11.4](/filings/0001493152-25-021881.md) | [10.8](/filings/0001493152-25-021881.md) | [6.1](/filings/0001493152-26-037357.md) | [2.9](/filings/0001493152-26-037357.md) | [1.5](/filings/0001493152-26-037357.md) | [6.3](/filings/0001493152-25-021881.md) | [13.5](/filings/0001493152-26-037357.md) | [14.4](/filings/0001493152-26-037357.md) | [12.2](/filings/0001493152-26-037357.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(967) d](/filings/0001493152-24-045994.md) | [(2,439) d](/filings/0001493152-25-010352.md) | [(2,346)](/filings/0001641172-25-009933.md) | [(3,088) d](/filings/0001641172-25-023417.md) | [(4,329) d](/filings/0001493152-25-021881.md) | [1,266 d](/filings/0001493152-26-009881.md) | [(1,779)](/filings/0001493152-26-022697.md) | [(3,733) d](/filings/0001493152-26-037357.md) | [(4,204) d](/filings/0001493152-25-021881.md) | [(3,969) d](/filings/0001493152-26-009881.md) | [(3,442)](/filings/0001493152-26-022697.md) | [(3,675) d](/filings/0001493152-26-037357.md) |
| Capital expenditure | $k | [10.0 d](/filings/0001493152-24-045994.md) | [0.0 d](/filings/0001493152-25-010352.md) | not reported | not reported | [10.0 d](/filings/0001493152-25-021881.md) | [2.0 d](/filings/0001493152-26-009881.md) | not reported | not reported | [0.0 d](/filings/0001493152-25-021881.md) | [70.0 d](/filings/0001493152-26-009881.md) | [79.0](/filings/0001493152-26-022697.md) | [64.0 d](/filings/0001493152-26-037357.md) |
| Dividends paid | $k | [0.0 d](/filings/0001493152-23-040354.md) | [0.0 d](/filings/0001493152-24-009371.md) | [0.0](/filings/0001493152-24-019608.md) | [0.0 d](/filings/0001493152-24-032047.md) | [0.0 d](/filings/0001493152-24-045994.md) | [0.0 d](/filings/0001493152-25-010352.md) | [0.0](/filings/0001641172-25-009933.md) | [0.0 d](/filings/0001641172-25-023417.md) | [0.0 d](/filings/0001493152-25-021881.md) | [0.0 d](/filings/0001493152-26-009881.md) | [0.0](/filings/0001493152-26-022697.md) | [0.0 d](/filings/0001493152-26-037357.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [76.1](/filings/0001493152-23-040354.md) | [76.5](/filings/0001493152-24-019608.md) | [81.0](/filings/0001493152-24-032047.md) | [82.5](/filings/0001493152-24-045994.md) | [83.5](/filings/0001641172-25-009933.md) | [84.6](/filings/0001641172-25-023417.md) | [85.8](/filings/0001493152-25-021881.md) | [87.8](/filings/0001493152-26-022697.md) | [88.0](/filings/0001493152-26-037357.md) | [92.0](/filings/0001493152-25-021881.md) | [98.9](/filings/0001493152-26-022697.md) | [100](/filings/0001493152-26-037357.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 100,202,178 at 2026-07-31, from the cover of the [10-Q filed 2026-08-12](/filings/0001493152-26-037357.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.